Xiaoshan M. Shao

Jul 20, 2023 | nature.com | Yunxiao Yang |Xiaoshan M. Shao |Kellie N. Smith |Valsamo Anagnostou

AbstractIdentifying neoepitopes that elicit an adaptive immune response is a major bottleneck to developing personalized cancer vaccines. Experimental validation of candidate neoepitopes is extremely resource intensive and the vast majority of candidates are non-immunogenic, creating a needle-in-a-haystack problem.